Day One Biopharmaceuticals reiterates $225M-$250M OJEMDA revenue target as pipeline expands with Emi-Le integration
Source: SeekingAlpha
2026-02-25 06:12:10 ET
More on Day One Biopharmaceuticals
- Day One Biopharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish
- Day One Biopharmaceuticals reports Q4 results
- Day One Biopharmaceuticals Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration
Day One Biopharmaceuticals Inc.
NASDAQ: DAWN
DAWN Trading
0.14% G/L:
$21.295 Last:
2,667,853 Volume:
$21.29 Open:
DAWN Latest News
March 06, 2026 06:09:06 pm
Stock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East Tensions
March 06, 2026 04:01:00 pm
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
DAWN Stock Data
$1,169,987,345
82,448,428
0.79%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Brisbane
